49561-96-8Relevant academic research and scientific papers
17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
-
Paragraph 0847, (2014/03/21)
The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
Anti-Inflammation Compounds
-
Paragraph 0164; 0166, (2014/06/23)
The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C═O, C═S, OP(O)(O), P═O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
-
Page/Page column 132, (2012/04/04)
The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
ANTI-INFECTIVE COMPOUNDS
-
Page/Page column 26, (2011/10/10)
The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
-
Page/Page column 17, (2008/06/13)
The present invention relates to compounds and methods useful as inhibitors of PPAR, particularly PPARδ, and for the treatment or prevention of PPAR-mediated diseases, including metabolic diseases.
PROCESS FOR PREPARING 2-(4-TRIFLUOROMETHOXYPHENYL)ETHYLAMINE AND 4-BROMOMETHYL-AND 4-CHLOROMETHYL-1-TRIFLUOROMETHOXYBENZENE
-
, (2008/06/13)
The invention relates to a process for preparing 2-(4-trifluoromethoxyphenyl)ethylamine in an advantageous manner by (a) converting trifluoromethoxybenzene by halomethylation into halogenomethyl-1-trifluoromethoxybenzene, (b) converting the halogenomethyl
Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
-
, (2008/06/13)
Methods, compounds and compositions are provided for inhibiting the growth of pathogenic microbes in vitro and of treatment of pathogenic bacterial infections, such as mycobacterial, Clostridium, Cryptosporidium and Helicobacter infections, in vivo using bicyclic nitroimidazole compounds of the formula (II): STR1 wherein R1 is hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocycle, substituted heterocycle and heterocyclicalkyl; X is oxygen, sulfur or NR2, where R2 is hydrogen, loweralkyl, aryl, cycloalkyl, heterocycle, substituted heterocycle, heterocyclicalkyl, COR3 or SO2 R4 CONR4 R5, where R3, R4 and R5 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyaryl, alloxyalkoxyaryl, alkylheterocycle, and alkoxyheterocycle; n is 1, 2 or 3; Y and Z are independently selected from oxygen, CH2, CO, CR4 R5 or NR4, where R4 and R5 are as defined above; provided that when n is 2 or 3, the compounds of formula II can be additionally substituted as follows: STR2 wherein R6, R7, R8 and R9 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyalkylaryl, alkoxyalkylheterocycle, alkylary2alkylaryl, alkylarylaryl, alkylcycloalkyl, alkoxyaryl, alkylheterocycle, and alkoxyheterocycle; and the pharmaceutically acceptable salts thereof.
